跳至主要内容
临床试验/NCT02795403
NCT02795403已完成不适用

Hepatitis C Virus Particles-bound Human Proteins : Identification in Clinical Samples and Implication in the Viral Life Cycle

Hospices Civils de Lyon2 个研究点 分布在 1 个国家目标入组 10 人开始时间: 2011年1月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
10
试验地点
2
主要终点
Qualitative identification (unit used: Protein Prophet score) of a given virion-bound protein in purified virions preparations

研究概览

简要总结

The emergence of hepatocellular carcinoma (HCC) has prompted a search for a thorough understanding of the biology of one of its major causative agents, the hepatitis C virus (HCV). HCV particles acquire via budding and encapsidation cellular proteins. There is mounting evidence on several viral species that virion-bound proteins are prone to be involved either at the replication, budding/egress or entry/release steps of the viral cycle.

Identifying such targets may yield ideal candidates for gaining insight on the dependence of HCV upon a restricted subset of host proteins, therefore providing refined sets of genetically stable targets for therapy. This project's goals are to set up adequate conditions for robust and reproducible purification of HCV virions in clinical samples, followed by the identification of their HCV-bound host proteins and the characterization of their functions. Proteomics profiling of HCV particles purified from clinical samples will be overlaid with proteins identified and characterized in cell culture grown HCV particles during my post-doctoral training, using clinical biomarker discovery grade criteria. Targets identified in both samples sets will be subjected to in vitro investigations using HCV-replicating cells. Conventional biochemical and imaging methods will be used in order to: (i) ascertain their physical association with HCV virions; (ii) define the modalities of their interaction with HCV proteins; (iii) decipher the topology and subcellular localization of their association with HCV proteins and virions; (iv) quantitatively assess their functional involvement in particle budding, egress or secretion and infectivity. A candidate that yielded satisfactory results in these experiments will be disclosed and further investigated at the level of structural biology, in collaborative research programs.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Basic Science
盲法
Single (Investigator)

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Adult> 18 and <60 years
  • Infected with HCV genotype 1 HCV antibody positive.
  • positive viremia for more than 6 months
  • Viremia> 106 IU / ml.
  • nonresponders to previous treatment and without antiviral treatment for 2 months.
  • For control samples: Patients responders to previous treatment and without antiviral treatment for 2 months.

排除标准

  • Patient receiving or having received antiviral treatment within two months.
  • patient with against-indication for a blood sample of 150 ml
  • immunosuppressive therapy patient
  • Patient with liver disease other than hepatitis C.
  • Patients with cirrhosis.
  • patient with hepatocellular carcinoma.
  • Patients with one or more severe co-morbidities defined as:
  • Co-infection with HIV or HBV.
  • hematological malignancies changing or aplasia
  • Insulin-dependent diabetes
  • dialyzed chronic renal failure
  • Heart failure
  • Persons subject to legal protection or the subject of a safeguard measure of justice not affiliated with a social security scheme or not beneficiaries of such a scheme
  • Pregnant women

结局指标

主要结局

Qualitative identification (unit used: Protein Prophet score) of a given virion-bound protein in purified virions preparations

时间窗: One to two years after mass spectrometry identification of the candidate

Protein prophet scores allow one to estimate the robustness of identification of a given protein in MS approaches.

Quantitative evaluation of its implication in viral morphogenesis (unit used: TCID50).

时间窗: One to two years after mass spectrometry identification of the candidate

TCID50 units are infectivity units routinely used in HCV research for viral infectivity quantification.

Quantitative evaluation of viral entry (unit used: HCV RNA /GUS mRNA copy ratios).

时间窗: One to two years after mass spectrometry identification of the candidate

HCV RNA /GUS mRNA copy ratios are derived from the 2\^delta(delta Ct) method.

次要结局

  • Comparison of clinical virions datasets with in vitro grown virions datasets(One to two years after mass spectrometry identification of the candidate)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验

HCV Virions Bound Proteins | 临床试验